NASDAQ · Health care

Artelo Biosciences, Inc. (ARTL)

It posted a net loss of $12.7M. At June 30, 2026 it held $4.2M in cash. Its latest periodic report to the SEC is the quarterly report (amended) (10-Q/A) filed on August 20, 2026.

Price

$4.54

-12.19% on the day · September 25, 2026

52-week range $3.45 to $179.19

Market cap

$20.9M

What Artelo Biosciences, Inc. does

Artelo Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARTL.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$11.4M	-$12.9M	-$12.52	n/a
2024	n/a	-$10.1M	-$9.8M	-$18.30	n/a
2023	n/a	-$9.9M	-$9.3M	-$18.84	n/a
2022	n/a	-$10.3M	-$10.1M	n/a	n/a
2022	n/a	-$9.4M	-$9.4M	n/a	n/a
2021	n/a	-$7.4M	-$7.4M	-$2.40	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: about 85 days after its last report of August 12, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Artelo Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 27, 2026
Shareholder rights changed 8-K
August 20, 2026
Quarterly report (amended) 10-Q/A · period to June 30, 2026Diluted EPS -$0.89 versus -$16.86.
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 13, 2026
Passive stake changed SCHEDULE 13G/A
August 12, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.89 versus -$16.86.
July 17, 2026
Shareholder vote results 8-K
July 16, 2026
Additional proxy material DEFA14A
July 16, 2026
Additional proxy material DEFA14A
July 2, 2026
Additional proxy material DEFA14A
June 22, 2026
Form PRER14A filing PRER14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 21, 2026. Insider transactions on SEC

Insider trades

What the people running Artelo Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about ARTL

What does Artelo Biosciences, Inc. do?

Artelo Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ARTL.

Is Artelo Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $12.7M.

When did Artelo Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (amended) (10-Q/A) filed on August 20, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder rights changed from August 27, 2026.

Similar companies

Compare ARTL with

Compare ARTL with any company

Follow ARTL

Get an email when Artelo Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ARTL: get an email when it files

Where the numbers come from

Financial figures are the values Artelo Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.